REG - N4 Pharma PLC - Broker Offer to raise a maximum of £1 million

N4 PharmaAnnouncement

18/11/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221118:nRSR8282Ga&default-theme=true

RNS Number : 8282G  N4 Pharma PLC  18 November 2022

18 November 2022

 

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Broker Offer to raise a maximum of £1 million

 

 

·    N4 Pharma (AIM: N4P) announces a Broker Offer through Turner Pope
Investments (TPI) Limited ("TPI")

 

·    The Issue Price of the Broker Offer is 2 pence per new ordinary share

 

·    Existing Shareholders or other interested parties who wish to
register their interest in participating in the Broker Offer should click on
the following TPI platform link: N4 Pharma Broker Offer
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fr%2FT1NwuLTc7b&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C4f2cd6e21a26487666d108dac896f44f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638042847908576330%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZTwQMELPoVJRhmFZwYB6Q4ViTnJPTGPnKcyMqUTybQk%3D&reserved=0)

 

·    The Broker Offer has an initial expected value of £0.25 million but
may be extended, with the express agreement of the Company, to £1.0 million
in the event the Broker Offer is oversubscribed

 

·    All bids communicated to TPI under the Broker Offer are subject to
review and acceptance by the Company and TPI and priority will be given to
existing shareholders in the event of oversubscription

 

·    The Broker Offer remains open until 4:30 p.m. on Monday, 21 November
2022

 

 

Broker Offer through TPI

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, wishes to
provide an opportunity for shareholders and other investors who did not
participate in the fundraising announced today to invest in the Company.

 

Under the Placing Agreement, TPI has been granted an option in the form of a
broker offer ("Broker Offer") under which TPI will, as agent for the Company,
invite subscriptions for additional new ordinary shares of 0.4p each in the
Company ("Broker Offer Shares") with an initial expected value of £0.25
million at the issue price of 2p ("Issue Price").  The Broker Offer may be
extended, with the express agreement of the Company, to £1.0 million in the
event the Broker Offer is oversubscribed.  Accordingly, the maximum number of
Broker Offer Shares to be issued under the Broker Offer at the Issue Price is
50,000,000.

 

The Broker Offer opens immediately and will close at 4.30pm on Monday, 21
November 2022.

 

As far as is practical, participation in the Broker Offer will be prioritised
for shareholders (direct or indirect) on the register at the close of business
on 17 November 2022 ("Existing Shareholders").

 

To subscribe for Broker Offer Shares, Existing Shareholders or other
interested parties who wish to register their interest in participating in the
Broker Offer should click on the following link : N4 Pharma Broker Offer
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.office.com%2Fr%2FT1NwuLTc7b&data=05%7C01%7CAndy.Thacker%40TurnerPope.com%7C4f2cd6e21a26487666d108dac896f44f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638042847908576330%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=ZTwQMELPoVJRhmFZwYB6Q4ViTnJPTGPnKcyMqUTybQk%3D&reserved=0)

 

A further announcement will be made following the end of the period during
which the Broker Offer is open.  If the Broker Offer is not fully subscribed
by 4.30 p.m. on 21 November 2022, orders from eligible investors will be
satisfied in full, and the balance of the Broker Offer shall lapse.

 

 

 

Enquiries:

 

 N4 Pharma plc
 Nigel Theobald, CEO                                         Via IFC Advisory
 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                              Tel: +44(0)20 3470 0470
 Nominated Adviser and Joint Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                       Tel: +44(0)20 3657 0050
 Joint Broker
 Andy Thacker

 James Pope

 IFC Advisory Ltd                                            Tel: +44(0)20 3934 6630
 Financial PR
 Graham Herring
 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity.  As these products progress through preclinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGMWGUPPGMM